Merck KGaA doesn't like sharing a name; AbbVie extends $21B Pharmacyclics offer; Xarelto wins new use in China;

@FiercePharma: Busy WuXi starts construction on China's largest biologics manufacturing plant. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: Drug shortages become way for Mylan to parry against Teva but will the FTC care? ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

> Germany's Merck KGaA continues to lament the fact that it shares its name with Merck ($MRK), the U.S.-based drug giant. Report (sub. req.)

> AbbVie ($ABBV) extended its $21 billion tender offer for Pharmacyclics ($PCYC) for the second time, with a new deadline of May 15. Report (sub. req.)

> Bayer said its anticoagulant Xarelto is now approved for three indications in China. Report

> Generic formulations of the Novartis ($NVS) transplant-rejection med Prograf (tacrolimus) perform as well as their branded counterpart, University of Cincinnati researchers found in a new study. Report

> Long-term data on complications with a Bayer contraceptive device, Essure, has patients and others petitioning FDA to pull its approval. Report

Medical Device News

@FierceMedDev: ICYMI: Greatbatch spins off neurostimulation unit to speed up growth. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDiagnostics: Drug testing company Cordant raises $12.8M as it seeks to be fragmented industry's one-stop shop. Story | Follow @VarunSaxena2

@EmilyWFierce: Novartis faces more kickback scrutiny after $45M Express Scripts settlement. FiercePharma story | Follow @EmilyWFierce

> China launches probe against three med tech multinationals over bribery suspicions. Story

> Under FDA investigation, Bayer releases new data on Essure contraceptive with a positive twist. Article

Biotech News

@FierceBiotech: A gene therapy 'cure' for blindness starts to fade within a few years. Report | Follow @FierceBiotech

@JohnCFierce: Pharma wants to avoid "Gilead's gaffe?" Really? I assume you mean they want to avoid the controversy, keep the $$$. More | Follow @JohnCFierce

> Bayer fronting $155M for a promising anticoagulant from Isis Pharma. Report

> Acucela's founder wrests back the reins after proxy battle. Story

> Waksal's new biotech spins out its gene therapy biz with an IPO in mind. Article

Animal Health News

> VCA animal hospitals report higher Q1 earnings. More

> Missouri scientists seek public's help in quest to sequence feline genomes. Report

> IDEXX misses earnings target, dampens 2015 forecast. Story

> Chicken producer Tyson to ditch human antibiotics in 2017. Item

> High-flyer Akorn crashes on earnings restatement as shareholders sue en masse. Article

Biotech IT News

> Genentech joins WaferGen's single cell analysis early-access program. Item

> GSK's social media savvy bags it 2nd place in digital ranking of big British businesses. More

> Apple Watch's data-gathering functions fall short of expectations. Story

> California calls for precision medicine pilot proposals. Report

> Congress keeps trial data sharing plan in slimmed-down 21st Century Cures Act. Article

And Finally... Costco ($COST) accused Johnson & Johnson's ($JNJ) eye care unit of fixing prices on contact lenses. Report (sub. req.)

Suggested Articles

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.

A drumbeat of anecdotal evidence and high-level praise for hydroxychloroquine in patients with COVID-19 spurred the FDA to grant an emergency nod.